Astrazeneca (AZN) Rises Higher Than Market: Key Facts

Astrazeneca (AZN) closed at $166.68, up 2.87% in the latest session, outperforming the S&P 500. The pharmaceutical company is trading at a Forward P/E of 17.28, below its industry average of 25.3, suggesting a valuation discount. However, the stock holds a Zacks Rank #3 (Hold) rating with projected Q3 EPS declining 9.24% year-over-year, though full-year earnings are expected to grow 2.4%. The Medical - Biomedical and Genetics industry ranks in the bottom 38% of all industries.